Otros proyectos internacionales

Molecular Diagnosis, Prognosis, and Therapeutic Targets in Mantle Cell Lymphoma

IP: CAMPO GUERRI, ELIAS
Financiador: Mayo Clinic Arizona
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: NIH_PAR-16-457_01
Importe: 680.686,05 €
Duración: 19/09/2018 to 31/08/2023

II Synergy Workshop on Translational and Clinical Oncology applied to Environmental & Occupational Cancer: Focus on Radon.

IP: MEZQUITA PEREZ, LAURA
Financiador: BUNDESAMT FUER STRAHLENSCHUTZ
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: H2020-NFRPCURS_25_01
Importe: 12.000 €
Duración: 01/09/2024 to 31/08/2025

Efecto del Tratamiento agudo con corticoides endovenosos en las partes blandas en fracturas de pilón tibial, retropié y mediopié en relación con tiempo desde ingreso hasta tratamiento quirúrgico

IP: GARCIA ELVIRA, RUBEN
Financiador: AO Foundation AO Global Networks
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 2021-AOTESASPAIN_003
Importe: 7.254,75 €
Duración: 15/01/2022 to 30/09/2025

MOLECULAR MEASURABLE RESIDUAL DISEASE (MRD) MONITORING BY HIGH-THROUGHPUT TECHNIQUES IN PATIENTS TREATED WITH CART19 THERAPY

IP: LOPEZ GUERRA, MONICA
Financiador: Thermo fisher scientific inc.
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: THERMOONCOCRG_22_01
Importe: 186.393,29 €
Duración: 28/06/2023 to 30/09/2025

Early detection of perianal fistulizing - Early detection of perianal fistulizing disease- Pathophysiology and Imaging

IP: SALAS MARTINEZ, MARIA AZUCENA
Financiador: THE LEONA M & HARRY B HELMSLEY CHARITABLE TRUST
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 2008-04050
Importe: 1.745.753 €
Duración: 25/11/2019 to 28/11/2025

HUNTER: Hepatocellular Carcinoma Expediter Network

IP: LLOVET BAYER, JOSEP MARIA
Financiador: Newcastle University Accounts Payable
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: AA_17_03
Importe: 0,01 €
Duración: 01/11/2018 to 30/11/2025

CRCNS US-Spanish Research Proposal: Circuit mechanisms of priors and learning during decision making

IP: DE LA ROCHA VAZQUEZ, JAIME
Financiador: Massachussets Institute of Technology
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: NSF_CRCNS_21_01
Importe: 0,01 €
Duración: 01/12/2022 to 30/11/2025

Psoriasis, a metabolic dysregulation of the innate immune system? Targeting ZEB1 in macrophages as a new therapeutic approach to psoriasis

IP: POSTIGO ANGON, ANTONIO ANDRES
Financiador: LEO FOUNDATION
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LEO_19_01
Importe: 491.478 €
Duración: 01/03/2020 to 31/12/2025

PPMI - Parkinson's Progression Markers Initiative (PPMI) study

IP: ALDECOA ANSORREGUI, IBAN
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-024484
Importe: 52.683,78 €
Duración: 01/01/2021 to 31/12/2025

Deciphering the molecular signatures of gestational food cravings as drivers of eating disorders in the offspring

IP: HADDAD TOVOLLI, ROBERTA
Financiador: Brain and Behaviour Research Foundation
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: BBRF_YI_23
Importe: 64.218 €
Duración: 15/01/2024 to 14/01/2026

Effects of circulating extracellular vesicles on pancreatic islets during obesity

IP: SERVITJA DUQUE, JOAN MARC
Financiador: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EFSD/BOEHR_22_01
Importe: 100.000 €
Duración: 09/01/2023 to 31/01/2026

A new target for the treatment of acute and chronic itch

IP: Gasull Casanova, Xavier
Financiador: LEO FOUNDATION
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LF-OC-22-001114
Importe: 351.488,65 €
Duración: 01/02/2023 to 31/01/2026

Type 2 inflammation and olfactory loss in chronic rhinosinusitis with nasal polyps: Role of Mepolizumab in olfactory cell neurogenesis

IP: MULLOL MIRET, JOAQUIM
Financiador: Glaxosmithkline Research & Development Limited
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 14859
Importe: 389.318,8 €
Duración: 01/09/2023 to 14/03/2026

Preclinical evaluation of Lilly LRRK2 inhibitors for Parkinson's disease using phosphoproteomic analysis

IP: EZQUERRA TRABALON, MARIO ANTONIO
Financiador: LILLY, SAU
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LILLY_RAP_23_01
Importe: 242.258,79 €
Duración: 19/03/2024 to 18/03/2026

Dissecting the role of the 14q32 region in hepatoblastoma "Hblast14"

IP: SANCHO BRU, PAU
Financiador: Worldwide Cancer Research
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 23-0356
Importe: 245.573,14 €
Duración: 01/04/2023 to 31/03/2026

Dissecting the cellular and molecular atlas of Rheumatoid Arthritis (RA) in sustained remission to identify pathways maintaining Remission and Triggering Flares

IP: CAÑETE CRESPILLO, JUAN DE DIOS
Financiador: FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: FOREUM_21_02
Importe: 90.000 €
Duración: 01/04/2023 to 31/03/2026

Cell-Specific Epigenomic Changes in iPSC-Derived Oligodendrocytes from MSA Patients: Effects of α-Synuclein Fibril Exposure in a Disease-Specific Cell Model

IP: COMPTA HIRNYJ, YAROSLAU
Financiador: King Baudouin Foundation - EVPA
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: KBF_MSA_24_01
Importe: 9.567,58 €
Duración: 22/05/2025 to 21/05/2026

Decoding tanycytic mitochondrial dynamics in nutrient sensing and metabolic health.

IP: CLARET CARLES, MARC
Financiador: EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EFSD/LILLY_23_01
Importe: 100.000 €
Duración: 01/07/2024 to 30/06/2026

COVID-19 in patients under treatment with anti-CD20 monoclonals: clinical features and outcome

IP: SORIANO VILADOMIU, ALEJANDRO
Financiador: GILEAD SCIENCES, INC
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: GILEAD_ESR_24_01
Importe: 158.224 €
Duración: 08/07/2025 to 07/07/2026

Mutimodal single cell profiling of tumor cell and microenvironment interactions driving clinical evolution and therapeutic responses in Mantle Cell Lymphoma

IP: CAMPO GUERRI, ELIAS
Financiador: ASTRAZENECA UK LTD.
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ASTRAZ_HEMAT_22_1
Importe: 647.255,72 €
Duración: 04/08/2022 to 03/08/2026

EHIN - Epithelioid Hemangioendothelioma International Network.

IP: RIMOLA GIBERT, JORDI
Financiador: EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EASL_RG_21_01
Importe: 50.000 €
Duración: 01/09/2021 to 31/08/2026

RIBOLARIS-PREDICT - Genomic-Based Biomarkers for Predicting Ribociclib Response in Early-Stage Hormone Receptor-Positive and HER2-Negative Breast Cancer (RIBOLARIS-PREDICT)

IP: PRAT APARICIO, ALEIX
Financiador: Breast Cancer Research Foundation - BCRF
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: BCRF_AAP_24
Importe: 200.213,66 €
Duración: 01/10/2024 to 30/09/2026

ATLAX - Characterizing the signals from adipo-liver axis in NASH and unveiling their utility as disease biomarkers.

IP: GRAUPERA GARCIA MILA, ISABEL
Financiador: Pfizer International LLC
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: PFIZER_NASH_A_22_1
Importe: 127.775,17 €
Duración: 08/11/2023 to 31/12/2026

Single cell subclonal characterization and evolution of the genome and transcriptome in IgM monoclonal gammopathy

IP: MORENO FAJARDO, DAVID FERNANDO
Financiador: International Waldenstrom's Macroglobulinemia Foundation
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: IWMF_KCDA_24_01
Importe: 146.603,01 €
Duración: 17/02/2025 to 16/02/2027

Transcriptomic impact of blocking IL-5 with mepolizumab on CD4+T lymphocytes from patients with EGPA. Search for predictors of response

IP: ESPIGOL FRIGOLE, GEORGINA
Financiador: Glaxosmithkline Research & Development Limited
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 219739
Importe: 164.895,2 €
Duración: 08/09/2023 to 26/02/2027

Enabling Artificial Intelligence (AI) for Early Detection of Melanoma in Smartphone Images

IP: MALVEHY GUILERA, JOSE
Financiador: SLOAN KETTERING INSTITUTE FOR CANCER RES
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MRA_TSA_24_01
Importe: 72.285 €
Duración: 01/06/2024 to 31/05/2027

PREDICTION OF TREATMENT NEEDS USING A HYBRID ARTIFICIAL INTELLIGENCE-BASED MANAGEMENT ASSISTANT (ALMA) TOOL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

IP: ZARRANZ VENTURA, JAVIER
Financiador: Foundation of the Society of Retina Specialists
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EURETINA_24_1
Importe: 227.503 €
Duración: 01/06/2025 to 31/05/2027

MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapY (MULTIPLY)

IP: BEA BOBET, SILVIA MARGARITA
Financiador: Ludwig-Maximilians-Universitaet Muenchen
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: LLS_MCL_22_2
Importe: 221.720 €
Duración: 01/07/2023 to 30/06/2027

BioRTC Computational Neuroscience Course

IP: COMPTE BRAQUETS, ALBERT
Financiador: Simons Foundation
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 00009921
Importe: 71.009,28 €
Duración: 01/09/2024 to 31/08/2027

RICHARDIII - A pilot study on the use of ARI-0003 cells (dual anti-CD19/CD9 chimeric antigen receptor T-cells) for patients with relapsed/refractory Richter's transformation

IP: DELGADO GONZÁLEZ, JULIO
Financiador: Cancer Research Institute
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: INT_CRI_CIG_23_01
Importe: 942.595,99 €
Duración: 01/01/2025 to 31/12/2027

HeBA - Barcelona 2022 PPMI Healthy Brain Aging Initiative

IP: MARTI DOMENECH, MARIA JOSEFA
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-022187
Importe: 968.050,79 €
Duración: 01/06/2022 to 30/11/2028

CARTALLEU - Phase 2 clinical trial to evaluate the efficacy and safety of varnimcabtagene autoleucel for relapsed/refractory adult acute lymphoblastic leukaemia

IP: DELGADO GONZÁLEZ, JULIO
Financiador: FUNDACIÓN CIENTIFICA ASOCIACIÓN ESPAÑOLA CONTRA EL CANCER
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ATTRACT_23_01
Importe: 0,01 €
Duración: 01/04/2024 to 31/03/2029

PF_MARFANS_Egea - Financiación para un proyecto de investigación liderado por el Dr. Egea

IP: Egea Guri, Gustavo
Financiador: MARFANS
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: 12498-25 FRCB
Importe: 400.000 €
Duración: 06/06/2025 to 01/09/2029

MULTICENTER TRIAL OF VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (CART19-BE-02 TRIAL)

IP: LOPEZ GUILLERMO, ARMANDO
Financiador: EHA (EUROPEAN HEMATOLOGY ASSOC.)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: EHA-EBMT_AWARD_01
Importe: 10.000 €
Duración: 01/07/2025 to 30/06/2030

BLOOD a-SYNUCLEIN AGGREGATION ASSAY AS A NOVEL DIAGNOSTIC TOOL FOR PARKINSON’S DISEASE

Beneficiario: DE MENA ALVAREZ, LORENA
Director: FERNANDEZ SANTIAGO, RUBEN
Financiador: US Department of Defence
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: DOD_PRP_23_01
Importe: 328.679,43 €
Duración: 01/09/2024 to 31/08/2026

The Edmond J. Safra Fellowship in Movement Disorders - Hospital Clinic Barcelona

Beneficiario: LAZARO HERNANDEZ, CARLOS
Director: VALLDEORIOLA SERRA, FRANCESC
Financiador: Michael J. Fox Foundation for Parkinson
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: MJFF-023487
Importe: 170.928 €
Duración: 01/09/2023 to 31/08/2026

RETRACER - RET Expression TRacking to Assess CDK4/6-Inhibitor and Endocrine therapy Resistance emergence

Beneficiario: DI GRAZIA, GIUSEPPE
Director: SCHETTINI, FRANCESCO
Financiador: EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ESMO_2025_01
Importe: 61.000 €
Duración: 01/03/2026 to 28/02/2027

KALYX - (KRAS And Lung cancer: eXposome study) - The exposome study in KRAS-mutant non-small cell cancer patients

Beneficiario: MEAZZA PRINA, MARCO
Director: MEZQUITA PEREZ, LAURA
Financiador: EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ESMO_2025_02
Importe: 61.000 €
Duración: 01/03/2026 to 28/02/2027

The ORCHID study - Overcoming Early Relapse on Adjuvant CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer: Mechanisms of Resistance and Therapeutic Strategies (The ORCHID Study).

Beneficiario: MARTINELLI, GIULIO
Director: BERGAMINO SIRVEN, MILANA ARANTZA A
Financiador: EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)
Entidad beneficiaria: FRCB-IDIBAPS
Referencia: ESMO_2025_03
Importe: 61.000 €
Duración: 02/02/2026 to 01/02/2027